Idorsia Ltd To Discuss PRECISION top-line results Transcript
Good afternoon, good morning, everyone. My name is Andrew Weiss. I'm the Head of Investor Relations and Corporate Communications here at Idorsia Pharmaceuticals. Welcome to our webcast to discuss the excellent results of the PRECISION trial Phase III study for aprocitentan in resistant hypertension, which we shared in a press release yesterday morning, European time.
With me on the call are our CEO, Jean-Paul Clozel; our Chief Scientific Officer, Martine Clozel; and our Head of Global Clinical Development, joining us on the mic for the first time today, Alberto Gimona. A big welcome to you, Alberto.
Thank you.
Next slide, please. So as a gentle reminder, before handing over the mic, I need to make you aware that we will be making forward-looking statements. You,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |